Myocardial protective effects of nicorandil during percutaneous coronary intervention in patients with unstable angina

Circulation Journal

Volumn 69, Issue 3, 2005, Pages 306-310

  Ju, Han Kim ^a   Myung, Ho Jeong ^a   Kyung, Ho Yun ^a   Kye, Hun Kim ^a   Dong, Koo Kang ^a   Seo, Na Hong ^a   Sang, Yup Lim ^a   Sang, Hyun Lee ^a   Yun, Sang Lee ^a   Young, Joon Hong ^a   Hyung, Wook Park ^a   Kim, Weon ^a   Young, Keun Ahn ^a   Jeong, Gwang Cho ^a   Jong, Chun Park ^a   Jung, Chaee Kang ^a  

^a Chonnam National University Medical School   (South Korea)

Author keywords

Angioplasty; Nicorandil; Percutaneous coronary intervention; Unstable angina

Indexed keywords

CREATINE KINASE MB; ISOSORBIDE DINITRATE; NICORANDIL; TROPONIN T;

ADULT; ANALYSIS OF VARIANCE; ANGIOCARDIOGRAPHY; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORONARY ARTERY BYPASS GRAFT; CREATINE KINASE BLOOD LEVEL; ECHOCARDIOGRAPHY; FEMALE; FOLLOW UP; HEART DEATH; HEART INFARCTION; HEART LEFT VENTRICLE EJECTION FRACTION; HUMAN; MAJOR CLINICAL STUDY; MALE; PERCUTANEOUS CORONARY INTERVENTION; RANDOMIZED CONTROLLED TRIAL; REVASCULARIZATION; UNSTABLE ANGINA PECTORIS;

AGED; ANGINA PECTORIS; ANGIOGRAPHY; ANGIOPLASTY, TRANSLUMINAL, PERCUTANEOUS CORONARY; BIOLOGICAL MARKERS; CARDIOTONIC AGENTS; ECHOCARDIOGRAPHY; FEMALE; HUMANS; ISOSORBIDE DINITRATE; MALE; MIDDLE AGED; NICORANDIL; STROKE VOLUME; TREATMENT OUTCOME;

EID: 20144377820     PISSN: 13469843     EISSN: None     Source Type: Journal    
DOI: 10.1253/circj.69.306     Document Type: Article

References (35)

1. Klein LW, Kramer BL, Howard E, Lesch M. Incidence and clinical significance of transient creatine kinase elevations and the diagnosis of non Q-wave myocardial infarction associated with coronary angioplasty. J Am Coll Cardiol 1991; 17: 621-626.
2. Oh JK, Shub C, Ilstrup DM, Reeder GS. Creatine kinase release after successful percutaneous transluminal coronary angioplasty. Am Heart J 1985; 109: 1225-1231.
3. Pauletto P, Piccolo D, Scannapieco G, Vescovo G, Zaninotto M, Corbara F, et al. Changes in myoglobin, creatine kinase and creatine kinase-MB after percutaneous transluminal coronary angioplasty for stable angina pectoris. Am J Cardiol 1987; 59: 999-1000.
4. Kim JH, Jeong MH, Sim DS, Lee SH, Hong YJ, Park OY, et al. The Usefulness of cardiac troponin as a marker detecting minor myocardial injury after percutaneous coronary intervention. Korean Circulation J 2002; 32: 413-419.
5. Akai K, Wang Y, Sato K. Vasodilatory effect of nicorandil on coronary arterial microvessels: Its dependency on vessel size and the involvement of the ATP-sensitive potassium channels. J Cardiovasc Pharmacol 1995; 26: 541-547.
6. Auchampach JA, Cavero I, Gross GJ. Nicorandil attenuates myocardial dysfunction associated with transient ischemia by opening ATP-dependent potassium channels. J Cardiovasc Pharmacol 1992; 20: 765-771.
7. Mizunuma T, Nithipatikom K, Gross GJ. Effects of nicorandil and glyceryl trinitrate on infarct size, adenosine release, and neutrophil infiltration in the dog. Cardiovasc Res 1995; 29: 482-489.
8. Dairaku Y, Miura T, Harada N, Kimura M, Okamura T, Iwamoto H, et al. Effect of ischemic preconditioning and mitochondrial KATP channel openers on chronic left ventricular remodeling in the ischemic-reperfused rat heart. Circ J 2002; 66: 411-415.
9. The IONA Study group. Effect of nicorandil on coronary events in patients with stable angina: The Impact Of Nicorandil in Angina (IONA) randomised trial. Lancet 2002; 359: 1269-1275.
10. Patel DJ, Purcell HJ, Fox KM. Cardioprotection by opening of the K(ATP) channel in unstable angina. Is this a clinical manifestation of myocardial preconditioning? Results of a randomized study with nicorandil: CESAR 2 investigation: Clinical European studies in angina and revascularization. Eur Heart J 1999; 20: 51-57.
11. Ito H, Taniyama Y, Iwakura K, Nishikawa N, Masuyama T, Kuzuya T, et al. Intravenous nicorandil can preserve microvascular integrity and myocardial viability in patients with reperfused anterior wall myocardial infarction. J Am Coll Cardiol 1999; 33: 654-660.
12. Kato T, Kamiyama T, Maruyama Y, Tanaka S, Yoshimoto N. Nicorandil, a potent cardioprotective agent, reduces QT dispersion during coronary angioplasty. Am Heart J 2001; 141: 940-943.
13. Ryan TJ, Faxon DP, Gunnar RM, Kennedy JW, King SB 3rd, Loop FD, et al. Guidelines for percutaneous transluminal coronary angioplasty. A report of the American College of Cardiology/American Heart Association task force on assessment of diagnostic and therapeutic cardiovascular procedures. Circulation 1988; 78: 486-502.
14. Sheehan FH, Braunwald E, Canner P, Dodge HT, Gore J, Van Natta P, et al. The effect of intravenous thrombolytic therapy on left ventricular function: A report on tissue-type plasminogen activator and streptokinase from the Thrombolysis in Myocardial Infarction (TIMI Phase I) trial. Circulation 1987; 75: 817-829.
15. Karim MA, Shinn M, Oskarsson H, Windle J, Deligonul U. Significance of cardiac troponin T release after percutaneous transluminal coronary angioplasty. Am J Cardiol 1995; 76: 521-523.
16. Hunt AC, Chow SL, Shiu MF, Chilton DC, Cummins B, Cummins P. Release of creatine kinase-MB and cardiac specific troponin I following percutaneous transluminal coronary angioplasty. Eur Heart J 1991; 12: 690-694.
17. Ravkilde J, Nissen H, Mickley H, Andersen PE, Thayssen P, Harder M. Cardiac troponin T and CK-MB mass release after visually successful percutaneous transluminal coronary angioplasty in stable angina pectoris. Am Heart J 1994; 127: 13-20.
18. Talasz H, Genser N, Mair J, Dworzak EA, Friedrich G, Moes N, et al. Side-branch occlusion during percutaneous transluminal coronary angioplasty. Lancet 1992; 339: 1380-1382.
19. Katus HA, Remppis A, Neumann FJ, Scheffold T, Diederich KW, Vinar G, et al. Diagnostic efficiency of troponin T measurements in acute myocardial infarction. Circulation 1991; 83: 902-912.
20. Rottbauer W, Greten T, Muller-Bardorff M, Remppis A, Zehelein J, Grunig E, Katus HA. Troponin T: A diagnostic marker for myocardial infarction and minor cardiac cell damage. Eur Heart J 1996; 17: F3-F8.
21. Antman EM, Tanasijevic MJ, Thompson B, Schactman M, McCabe CH, Cannon CP, et al. Cardiac-specific troponin I levels to predict the risk of mortality in patients with acute coronary syndromes. N Engl J Med 1996; 335: 1342-1349.
22. Lee SH, Jeong MH, Park JS, Kim W, Kim KH, Kang KT, et al. The long-term clinical significance of troponin and electrocardiogram in patients with unstable angina. Korean J Med 2001; 61: 506-517.
23. Fuchs S, Kornowski R, Mehran R, Lansky AJ, Satler LF, Pichard AD, et al. Prognostic value of cardiac troponin-I levels following catheter-based coronary interventions. Am J Cardiol 2000; 85: 1077-1082.
24. Nageh T, Sherwood RA, Harris BM, Thomas MR. Cardiac troponin I for risk stratification following percutaneous coronary artery intervention in acute coronary syndromes. Catheter Cardiovasc Interv 2002; 55: 37-42.
25. Cantor WJ, Newby LK, Christenson RH, Tuttle RH, Hasselblad V, Armstrong PW, et al. Prognostic significance of elevated troponin I after percutaneous coronary intervention. J Am Coll Cardiol 2002; 39: 1738-1744.
26. Murry CE, Jennings RB, Reimer KA. Preconditioning with ischemia: A delay of lethal cell injury in ischemic myocardium. Circulation 1986; 74: 1124-1136.
27. Mizumura T, Nithipatikom K, Gross GJ. Bimakalim, an ATP-sensitive potassium channel opener, mimics the effect of ischemic preconditioning to reduce infarct size, adenosine release, and neutrophil function in dogs. Circulation 1995; 92: 1236-1245.
28. Yellon DF, Alkuraifi AM, Pugsley WB. Preconditioning the human myocardium. Lancet 1993; 342: 276-277.
29. Matsubara T, Minatoguchi S, Matsuo H, Hayakawa K, Segawa T, Matsuno Y, et al. Three minutes, but not one minutes, ischemia and nicorandil have a preconditioning effect in patients with coronary artery disease. J Am Coll Cardiol 2000; 35: 345-351.
30. Sakai K, Yamagata T, Teragawa H, Matsuura H, Chayama K. Nicorandil enhances myocardial tolerance to ischemia without progressive collateral recruitment during coronary angioplasty. Circ J 2002; 66: 317-322.
31. Tsubokawa A, Ueda K, Sakamoto H, Iwase T, Tamaki S. Effect of intracoronary nicorandil administration on preventing no-reflow/slow flow phenomenon during rotational atherectomy. Circ J 2002; 66: 1119-1123.
32. Sugimoto K, Ito H, Iwakura K, Ikushima M, Kato A, Kimura R, et al. Intravenous nicorandil in conjunction with coronary reperfusion therapy is associated with better clinical and functional outcomes in patients with acute myocardial infarction. Circ J 2003; 67: 295-300.
33. Mizuo N, Iwao I, Yoshiya M, Yoshiaki S, Susumu N, Nehiro K, et al. Comparison between nicorandil and magnesium as an adjunct cardioprotective agent to percutaneous coronary intervention in acute anterior myocardial infarction. Circ J 2004; 68: 192-197.
34. Ueda H, Nakayama Y, Tsumura K, Yoshimaru K, Hayashi T, Yoshikawa J. Intravenous nicorandil can reduce the occurrence of ventricular fibrillation and QT dispersion in patients with successful coronary angioplasty in acute myocardial infarction. Can J Cardiol 2004; 20: 625-629.
35. Ikeda N, Yasu T, Kubo N, Hashimoto S, Tsuruya Y, Fujii M, et al. Nicorandil versus isosorbide dinitrate as adjunctive treatment to direct balloon angioplasty in acute myocardial infarction. Heart 2004; 90: 181-185.